Andy Cohen TRT: What He Said About Testosterone Therapy and What the Medicine Actually Means

What Andy Cohen Has Said About TRT

Andy Cohen has discussed testosterone replacement therapy in multiple public forums, making him one of the more forthcoming male celebrities on the topic. His statements are clinical starting points, not endpoints.

Cohen has referenced TRT on his SiriusXM radio show, in podcast interviews, and in social media posts, describing it as part of his personal health and wellness regimen. He has framed the therapy in the context of energy, vitality, and feeling like himself as he moved through his forties. In one appearance, he described the effect of testosterone therapy in terms of mood and physical drive, consistent with the symptom profile clinicians use to evaluate hypogonadism candidates.

The Direct Statements

Cohen has not released lab values or physician notes. His public disclosures are self-reported and anecdotal by nature. That distinction matters: a celebrity confirming TRT use tells you about his personal health decision, not about whether TRT is right for any other individual.

What he has said, paraphrased across multiple appearances: testosterone therapy changed how he felt day to day, he worked with a physician to access it, and he considers it a routine part of his medical care. He has spoken about it without shame or sensationalism, which likely contributes to the volume of searches his name generates on the topic.

Why Public Disclosure Matters Clinically

When public figures discuss hormone therapy candidly, patient inquiry to physicians tends to rise. A 2020 analysis in the Journal of General Internal Medicine found that celebrity health disclosures are associated with measurable increases in related medical consultations within 12 months. The practical takeaway: Cohen's openness may prompt men who have ignored fatigue, low libido, or mood changes to finally schedule a lab draw. That is not a bad outcome, provided the subsequent evaluation is evidence-based.

What TRT Actually Is: Clinical Definition and Mechanism

TRT is the medical administration of exogenous testosterone to men with confirmed hypogonadism. Confirmed means two separate fasting morning serum testosterone measurements below 300 ng/dL, accompanied by signs and symptoms, per the 2018 Endocrine Society Clinical Practice Guideline.

Testosterone acts on androgen receptors in muscle, bone, brain, adipose tissue, and the cardiovascular system. Declining endogenous production, whether from primary testicular failure or secondary hypothalamic-pituitary dysfunction, produces the recognizable cluster of symptoms Cohen and others have described publicly.

Formulations in Common Clinical Use

Testosterone is available in several delivery systems, each with distinct pharmacokinetics:

• Testosterone cypionate or enanthate (injectable): 100 to 200 mg intramuscular every 1 to 2 weeks, or 50 to 100 mg weekly to reduce peak-to-trough fluctuation. This is the most commonly prescribed form in U.S. Outpatient practice.
• Testosterone gel 1.62% (AndroGel, Testim): 20.25 to 81 mg applied transdermally daily. Steadier serum levels than biweekly injections, but transfer risk to partners and children requires precautions.
• Testosterone pellets (Testopel): 150 to 450 mg subcutaneous implant every 3 to 6 months. Less dosing flexibility once placed.
• Testosterone undecanoate (Aveed, Jatenzo): Long-acting injectable given at 0, 4, and then every 10 weeks, or oral capsule dosed twice daily with meals.

The FDA prescribing information for testosterone cypionate specifies that therapy is indicated for conditions associated with a deficiency or absence of endogenous testosterone, not for age-related decline alone.

Who Qualifies: The Two-Test Rule

The Endocrine Society guideline states: "We recommend making the diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone levels." That means one low reading is not sufficient. Levels must be confirmed on a second morning draw, ideally with total testosterone and free testosterone measured together when total testosterone falls in the 200 to 400 ng/dL borderline range.

Men with the following conditions are typically excluded from TRT or require careful risk-benefit discussion: prostate cancer, breast cancer, hematocrit above 54%, untreated obstructive sleep apnea, severe lower urinary tract symptoms, or active desire for fertility (because exogenous testosterone suppresses spermatogenesis via the hypothalamic-pituitary axis).

The Evidence Base: What Clinical Trials Show

The most rigorous TRT dataset in older men comes from the Testosterone Trials (TTrials), a set of seven coordinated, double-blind, placebo-controlled studies published between 2016 and 2017. The TTrials enrolled 790 men aged 65 or older with serum testosterone below 275 ng/dL and at least one symptom. Participants received testosterone gel 1% titrated to achieve levels of 500 to 1000 ng/dL or placebo gel for 12 months.

Physical Function and Bone

The TTrials Physical Function Trial found no statistically significant improvement in walking distance at 12 months in the testosterone group versus placebo (Snyder et al., NEJM 2016). Bone density, however, did improve: the TTrials Bone Trial showed that testosterone increased volumetric bone mineral density at the spine by 7.5% versus 0.6% for placebo (P<0.001) (Snyder et al., JAMA Internal Medicine 2017).

Sexual Function and Mood

The TTrials Sexual Function Trial showed that testosterone significantly improved sexual desire and erectile function scores at 12 months versus placebo (Cunningham et al., J Clin Endocrinol Metab 2016). The Vitality Trial found a modest but statistically significant improvement in fatigue scores, though the effect size was smaller than many patients expect.

Cardiovascular Signal

The TTrials Cardiovascular Trial reported a higher rate of coronary artery noncalcified plaque volume progression in the testosterone arm versus placebo at 12 months (Budoff et al., JAMA 2017). This finding generated significant regulatory and clinical attention. The FDA subsequently required a label update warning about possible increased cardiovascular risk, visible in the current testosterone prescribing label on FDA.gov.

The TRAVERSE trial, published in 2023 (N=5,246 men with hypogonadism and elevated cardiovascular risk), found that testosterone replacement was noninferior to placebo for major adverse cardiovascular events over a mean follow-up of 33 months (Lincoff et al., NEJM 2023). TRAVERSE does not eliminate the cardiovascular conversation, but it does provide reassurance in a properly selected population.

TRT Dosing, Monitoring, and the Standard of Care

Starting TRT without follow-up monitoring is not good medicine. The Endocrine Society recommends evaluating patients at 3 to 6 months after initiation and then annually. At each visit, the following should be assessed:

• Serum total testosterone (target mid-normal range: 400 to 700 ng/dL for most adult men)
• Hematocrit (hold or reduce dose if above 54%, given polycythemia risk)
• PSA (baseline and at 3 months; any increase above 1.4 ng/mL in the first year warrants urologic evaluation)
• Symptom response using a validated instrument such as the Aging Males Symptoms (AMS) scale
• Blood pressure and cardiovascular symptom review

Dose Adjustments in Practice

For testosterone cypionate, a common starting dose is 100 mg IM weekly. If trough testosterone (drawn just before the next injection) is below 400 ng/dL and symptoms persist, increasing to 150 mg weekly is reasonable. If hematocrit rises above 50%, reducing injection frequency or switching to a transdermal formulation flattens the peak and typically lowers red cell mass over 60 to 90 days.

Fertility Considerations

Men who want to preserve fertility should not start exogenous testosterone. It suppresses LH and FSH through negative feedback, causing intratesticular testosterone to fall and spermatogenesis to stop within weeks. Alternatives include clomiphene citrate 25 to 50 mg every other day or human chorionic gonadotropin (hCG) 500 to 1,000 IU three times weekly to maintain testicular function while raising serum testosterone. Both are off-label but supported by published case series and the American Urological Association's 2018 guidelines on male infertility.

TRT in Men Under 65: Where Cohen's Profile Likely Fits

The TTrials focused on men 65 and older. Cohen was born in 1968, placing him in his mid-fifties during the period he has discussed TRT use. The evidence in men aged 40 to 65 with symptomatic hypogonadism is less extensive but directionally consistent.

A 2014 meta-analysis in PLOS ONE covering 29 randomized controlled trials in men with low testosterone (mean age 51 years) found that testosterone therapy significantly improved sexual function (standardized mean difference 0.63, 95% CI 0.30 to 0.97) and modestly improved lean mass and reduced fat mass over 3 to 12 months. Mood and fatigue outcomes were more variable across studies.

Practical Implications for Middle-Aged Men

A man in his forties or fifties who presents with fatigue, decreased libido, difficulty with body composition despite adequate training, or low mood should receive a morning total testosterone draw as part of a standard metabolic workup. If two readings confirm hypogonadism, discussion of TRT is clinically appropriate. Cohen's public account aligns with this pattern. He has not claimed to be on TRT for performance enhancement or physique optimization, which would represent off-label use outside guideline boundaries.

The Concierge and Telehealth Dimension

A segment of TRT prescribing now occurs through telehealth and concierge practices. Access is faster, but the same diagnostic standards apply. Two low morning testosterone readings. Symptom documentation. Baseline labs including CBC, PSA, and metabolic panel. Any practice that bypasses these steps is not following the 2018 Endocrine Society guideline, regardless of how efficient the sign-up flow is.

Common Misconceptions About Celebrity TRT Disclosures

"He Must Be Taking It for Muscle"

Cohen is a television host, not an athlete. His public statements frame TRT around mood and energy, not physique. Men with genuine hypogonadism do experience modest improvements in lean mass (roughly 2 to 3 kg over 12 months in the TTrials cohort), but this is a side effect of hormone normalization, not the clinical rationale for therapy.

"You Can Just Ask Your Doctor for It"

Testosterone is a Schedule III controlled substance under the Controlled Substances Act. Prescribing it to a eugonadal man (normal testosterone levels, no symptoms) is outside FDA-approved indications and exposes both physician and patient to legal and medical risk. A provider who prescribes TRT without documented low levels is not practicing evidence-based medicine.

"TRT Is Permanent"

TRT does suppress the hypothalamic-pituitary-gonadal axis. If a patient stops, endogenous production may take 3 to 12 months to recover, and in some cases may not fully return. This is a conversation that should happen before the first injection. Men who stop TRT abruptly sometimes experience a symptomatic withdrawal period with fatigue, low mood, and reduced libido, often worse than the baseline that prompted therapy. Tapering with a post-cycle protocol using hCG and/or clomiphene may reduce recovery time, though evidence for specific protocols remains limited to small observational studies.

What Clinicians Think About Public Figures Discussing TRT

Dr. Shalender Bhasin, director of the Research Program in Men's Health at Brigham and Women's Hospital and lead investigator on multiple testosterone trials, has written that public discussion of testosterone therapy "has the potential to increase access for men who are genuinely deficient but also to drive inappropriate use in men with normal levels," noting that clinician gatekeeping through proper diagnosis is what separates therapy from misuse (Bhasin et al., NEJM 2010).

The Endocrine Society's 2018 guideline explicitly states: "We suggest against a universal starting age recommendation and instead recommend individualized decision-making based on symptom burden and confirmed biochemical deficiency." That language places the physician, not the patient or the celebrity interview, at the center of the prescribing decision.

TRT and Broader Hormone Health: What Men Should Actually Do

A celebrity disclosure is, at best, a prompt to act. Here is what acting looks like clinically:

1. Schedule a morning lab draw (before 10 a.m.) for total testosterone, free testosterone, LH, FSH, CBC, PSA, and a comprehensive metabolic panel.
2. If total testosterone is below 300 ng/dL, repeat the draw on a separate morning to confirm.
3. Document symptoms using the AMS scale or the ADAM questionnaire before your appointment so the visit is efficient.
4. Review the Endocrine Society guideline summary, freely available at endocrine.org.
5. If TRT is started, schedule a follow-up at 3 months for hematocrit, PSA, and testosterone level. Do not skip this visit.

Cohen's transparency about his own therapy does not change any of these steps for anyone else. What it may do is remove the stigma barrier that keeps some men from asking their physician a question they should have asked years earlier.